Literature DB >> 21036415

Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.

Akihiko Yoshida1, Koji Tsuta, Shun-ichi Watanabe, Ikuo Sekine, Masashi Fukayama, Hitoshi Tsuda, Koh Furuta, Tatsuhiro Shibata.   

Abstract

Primary adenocarcinoma with signet-ring cell component (Ad-SRCC) of the lung has been well characterized clinicopathologically and histologically, but their genetics has rarely been investigated. A recent report suggesting an association between Ad-SRCC and EML4-ALK fusion prompted us to undertake a histological, immunohistochemical, and molecular analysis of 10 cases of primary Ad-SRCC identified out of 699 lung adenocarcinomas (1.4%). Most of the Ad-SRCCs showed characteristic architectural as well as cytological features including cohesive clustering of signet-ring cells, a solid/acinar growth pattern, and alveolar filling at the tumor periphery. Diffuse co-expression of TTF-1 and p63 was observed in half of the Ad-SRCCs, and this immunoprofile has not been recognized previously. Four Ad-SRCCs (40%) harbored ALK translocations detected by reverse-transcriptase polymerase chain reaction, fluorescence in situ hybridization, and immunohistochemistry. One new EML4-ALK fusion variant was identified. One ALK-rearranged tumor showed focal squamous differentiation. None of the present Ad-SRCCs had EGFR or KRAS mutations, regardless of ALK status. This study successfully utilized tumor histology alone to identify a subset of adenocarcinomas showing a high rate of ALK translocation. The characteristic histology, immunoprofile, frequent ALK translocation, and total lack of EGFR or KRAS mutations, may suggest that Ad-SRCC forms a histologically/molecularly coherent subgroup of adenocarcinoma.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036415     DOI: 10.1016/j.lungcan.2010.09.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  31 in total

1.  An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.

Authors:  Robert J G Cardnell; Carmen Behrens; Lixia Diao; YouHong Fan; Ximing Tang; Pan Tong; John D Minna; Gordon B Mills; John V Heymach; Ignacio I Wistuba; Jing Wang; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 2.  Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.

Authors:  Hyojin Kim; Jin-Haeng Chung
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts.

Authors:  Jennifer M Boland; Jason A Wampfler; Jin S Jang; Xiaoke Wang; Michele R Erickson-Johnson; Andre M Oliveira; Ping Yang; Jin Jen; Eunhee S Yi
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

4.  Secretory myoepithelial carcinoma: a histologic and molecular survey and a proposed nomenclature for mucin producing signet ring tumors.

Authors:  Jassem M Bastaki; Bibianna M Purgina; Sanja Dacic; Raja R Seethala
Journal:  Head Neck Pathol       Date:  2014-01-21

Review 5.  Targeted inhibition in tumors with ALK dependency.

Authors:  Eunice L Kwak; Jeffrey W Clark; Alice T Shaw
Journal:  Lung Cancer (Auckl)       Date:  2013-01-09

6.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim Geisinger; Yasushi Yatabe; Yuichi Ishikawa; Ignacio Wistuba; Douglas B Flieder; Wilbur Franklin; Adi Gazdar; Philip S Hasleton; Douglas W Henderson; Keith M Kerr; Iver Petersen; Victor Roggli; Erik Thunnissen; Ming Tsao
Journal:  Arch Pathol Lab Med       Date:  2012-09-12       Impact factor: 5.534

Review 7.  Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.

Authors:  Eunhee S Yi; Jin-Haeng Chung; Kimary Kulig; Keith M Kerr
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

8.  The potential for crizotinib in non-small cell lung cancer: a perspective review.

Authors:  Yung-Jue Bang
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 9.  Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 10.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Authors:  Sai-Hong Ignatius Ou; Cynthia Huang Bartlett; Mari Mino-Kenudson; Jean Cui; A John Iafrate
Journal:  Oncologist       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.